Why the study?
Does acute hyperglycemia or hyperlipidemia reduce aspirin antiplatelet activity in diabetic subjects?
Does acute hyperglycemia or hyperlipidemia reduce aspirin antiplatelet activity in diabetic subjects?
Acute hyperlipidemia and hyperglycemia can acutely impair aspirin-mediated platelet inhibition in diabetic patients, potentially increasing cardiovascular risk.
Answers are grounded in this paper and cite their sources.
May indicate transient aspirin resistance after meals in diabetics; hypothesis-generating and requires prospective outcome trials before practice change.
Aspirin has lower antiplatelet activity in diabetic patients. Our aim is to study the roles of acute hyperglycemia and hyperlipidemia on aspirin function in diabetic subjects with and without cardiovascular disease. Using urine thromboxane (pg/mg creatinine) and VerifyNow (Aspirin Resistance Measures-ARU), we investigated diabetic subjects during a 2-hour glucose challenge (n = 49) or a 4-hour fat challenge (n = 11). All subjects were currently taking aspirin (81 or 325 mg). After fat ingestion, urine thromboxane increased in all subjects (Mean ± SE before: after) (1209 ± 336: 1552 ± 371, P = .01), while we noted a trend increase in VerifyNow measures (408 ± 8: 431 ± 18, P = .1). The response to glucose ingestion was variable. Diabetic subjects with cardiac disease and dyslipidemia increased thromboxane (1693 ± 364: 2799 ± 513, P < .05) and VerifyNow (457.6 ± 22.3: 527.1 ± 25.8, P < .05) measures after glucose. We conclude that saturated fat ingestion increases in vivo thromboxane production despite aspirin therapy.
No takes yet. Share an insight, caveat, or question.
Yassine et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: